Collect Product
Product Details
Materials Provided
IDComponentsSizeEP147-C01High-bind Plate1 plateEP147-C02Human TNFR215 μgEP147-C03Biotinylated Human TNF-alpha10 μgEP147-C04Anti-TNF-alpha Neutralizing Antibody20 μgEP147-C05Streptavidin-HRP10 μgEP147-C06Coating Buffer12 mLEP147-C0710xWashing Buffer50 mLEP147-C08Blocking Buffer50 mLEP147-C09Substrate Solution12 mLEP147-C10Stop Solution7 mLProduct Overview
TNF-alpha [Biotinylated] : TNFR2 Inhibitor Screening ELISA Kit is based on a competition-ELISA method, is used to screening for inhibitors of human TNF-alpha binding to human TNFR2. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human TNF-alpha binding to human TNFR2.
Reconstitution
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
Typical Data
Please refer to DS document for the assay protocol.
INHIBITION OF TNF-alpha [Biotinylated]: TNFR2 BINDING BY ANTI-TNF-alpha NEUTRALIZING ANTIBODY
Serial dilutions of Anti- TNF-alpha Neutralizing antibody (Catalog # EP147-C04) (1:1 serial dilution, from 10 μg/mL to 0.02μg/mL) was added into Biotinylated TNF-alpha: TNFR2 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
User Reviews Publish Comment
Frontier Progress
Drug Development Progress- English Name：
Tumor necrosis factor α
- Category：
- Listed Drugs Count：
68 Details
- Clinical Drugs Count：
74 Details
- Highest R&D Stage：
Approved
Contact Us
Drug Candidate Licensing
